2025 United States Asthma And Copd Drug Market Revenue Opportunities Report
Description
The 2025 United States Asthma And Copd Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma and COPD drug market in the United States are GlaxoSmithKline (GSK), AstraZeneca, Pfizer, and Merck & Co. GSK leads with its broad respiratory portfolio, including the blockbuster asthma drug Advair and newer biologics like depemokimab targeting severe asthma. AstraZeneca competes strongly with Symbicort, a combination inhaler showing rapid symptom relief, recently approved for broader patient use including severe asthma and COPD. Pfizer and Merck also hold significant market shares, investing heavily in respiratory drug development and marketing in North America, supported by the region's high asthma prevalence and R&D infrastructure.
GSK’s respiratory platform, including Ellipta inhalers and monoclonal antibodies, generates substantial revenue and innovation momentum. AstraZeneca focuses on biologics and digital inhaler technologies to differentiate its offerings. Pfizer and Merck engage through a diverse portfolio spanning pediatric and adult treatments. The U.S. market dominance is reinforced by about 25 million asthma patients and ongoing FDA approvals, with industry growth driven by advanced drug delivery systems and combination therapies. Market dynamics also reflect competitive advertising and expanded indications to capture both asthma and COPD patient segments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma and COPD drug market in the United States are GlaxoSmithKline (GSK), AstraZeneca, Pfizer, and Merck & Co. GSK leads with its broad respiratory portfolio, including the blockbuster asthma drug Advair and newer biologics like depemokimab targeting severe asthma. AstraZeneca competes strongly with Symbicort, a combination inhaler showing rapid symptom relief, recently approved for broader patient use including severe asthma and COPD. Pfizer and Merck also hold significant market shares, investing heavily in respiratory drug development and marketing in North America, supported by the region's high asthma prevalence and R&D infrastructure.
GSK’s respiratory platform, including Ellipta inhalers and monoclonal antibodies, generates substantial revenue and innovation momentum. AstraZeneca focuses on biologics and digital inhaler technologies to differentiate its offerings. Pfizer and Merck engage through a diverse portfolio spanning pediatric and adult treatments. The U.S. market dominance is reinforced by about 25 million asthma patients and ongoing FDA approvals, with industry growth driven by advanced drug delivery systems and combination therapies. Market dynamics also reflect competitive advertising and expanded indications to capture both asthma and COPD patient segments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
